Skip Navigation

Cardiovascular Research 2003 57(2):434-442; doi:10.1016/S0008-6363(02)00704-6
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Boer, R. A.
Right arrow Articles by van Veldhuisen, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Boer, R. A.
Right arrow Articles by van Veldhuisen, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Increased expression of cardiac angiotensin II type 1 (AT1) receptors decreases myocardial microvessel density after experimental myocardial infarction

Rudolf A. de Boera,b, Yigal M. Pintoa,b, Albert J.H. Suurmeijerc, Saraswati Pokharelb, Egbert Scholtensb, Michael Humlerd, Juan M. Saavedrad, Frans Boomsmae, Wiek H. van Gilsta,b and Dirk J. van Veldhuisena,*

aThoraxcenter, Department of Cardiology, Hanzeplein 1, 9713 GZ (PO Box 30.001, 9700 RB), University Hospital, Groningen, The Netherlands
bDepartment of Clinical Pharmacology, University Hospital, Groningen, The Netherlands
cDepartment of Pathology, University Hospital, Groningen, The Netherlands
dSection of Pharmacology, National Institutes of Mental Health, Bethesda, MD, USA
eDepartment of Internal Medicine/COEUR, University Hospital Dijkzigt, Rotterdam, The Netherlands

* Corresponding author. Tel.: +31-50-361-2355; fax: +31-50-361-4391. d.j.van.veldhuisen{at}thorax.azg.nl

Objective: To study the effects of increased levels of myocardial angiotensin II type 1 (AT1) receptor on microvascular growth following myocardial infarction (MI). Methods: MI was created in transgenic rats (TGR) with a cardioselective overexpression of the AT1 receptor. We used Sprague–Dawley (SD) rats as controls. Some of the rats were treated with the selective AT1 receptor blocker losartan (Los). Rats were sacrificed after 3 weeks. Results: MI caused left ventricular (LV) hypertrophy and LV dysfunction in both SD and TGR, which was prevented by AT1 receptor blockade. Furthermore, MI decreased microvessel density in the non-infarcted myocardium (SD MI: 1653±37/mm2, P<0.01 vs. sham-operated controls), however, microvessel density decreased significantly more in TGR with MI (1298±33/mm2, P<0.01 vs. SD MI). AT1 receptor blockade restored microvessel density (SD MI Los: 2046±195/mm2; TGR MI Los: 1742±47/mm2; P<0.01 vs. untreated). The differences in microvessel density were still present after correction for LV hypertrophy. The increase in microvessel density after AT1 receptor blockade was not accompanied by increased myocardial vascular endothelial growth factor (VEGF) levels. Microvessel density correlated with parameters of myocardial stretch, such as LV end-diastolic pressure (–0.681, P<0.001) and N-ANP (–0.424, P=0.01). Conclusions: Microvessel density after MI is decreased when the AT1 receptor is overexpressed, and this is amenable to AT1 receptor blockade. This suggests that efficacy of AT1 receptor blockers post-MI may not only be due to attenuation of LV remodeling, but also to a stimulatory effect on angiogenesis.

KEYWORDS Angiotensin; Growth factors; Infarction; Microcirculation; Receptors; Renin angiotensin system


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
P. van der Harst, A. A. Voors, W. H. van Gilst, M. Bohm, and D. J. van Veldhuisen
Statins in the treatment of chronic heart failure: Biological and clinical considerations
Cardiovasc Res, August 1, 2006; 71(3): 443 - 454.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.